News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News Flood of warning letters follows DTC ad clampdown The FDA has lost no time following through on its plan to tighten up DTC advertising of medicines, sending out dozens of untitled and warning letters.
News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
News FDA's Makary explains 'overdue' pharma ads crackdown FDA Commissioner Marty Makary has called DTC ads for medicines a "public health crisis" as the industry prepares for a regulatory crackdown.
News RFK Jr expands ACIP ahead of highly anticipated meeting Five members have been added to a controversial CDC vaccines panel ahead of a meeting this week that could have an impact on US immunisation policy.
News Rumour mill has Camurus buying partner Braeburn Camurus is said to be in talks to acquire US partner Braeburn in a deal that would give it control of their product for treating opioid use disorder.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.